Multiple myeloma In Rwanda: The need for further research

Addressing the rise of multiple myeloma in Rwanda

Durable responses in aRCC, how do we optimise treatment?

Bladder cancer updates from the first half of 2024

The combination of regorafenib, nivolumab and SCRT shows promising efficacy as neoadjuvant therapy for locally advanced RC

Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients

Biomarkers, predictive and prognostic factors of resistance to immunotherapy

GIST tumours and soft tissue sarcomas

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Uncommon genetic aberrations NTRK, RET, NRG

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma